Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression

MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/ -- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Urological Association (AUA) in Anaheim, California. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. An NDA for satraplatin is currently under priority review by the U.S. FDA.

"Patients with metastatic hormone-refractory prostate cancer frequently suffer from substantial pain associated with bone metastases. Thus, pain control for these patients constitutes a major challenge and is an important goal when caring for them," said Oliver Sartor, M.D., Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Associate Professor at Harvard Medical School, Boston, MA, and principal investigator of the SPARC trial, who is presenting the satraplatin data today. "In addition to the very encouraging results for progression-free survival demonstrating a 33% lower risk of progression compared to control, it is exciting to see that the SPARC trial results show that treatment with satraplatin also results in a statistically significant improvement in time to pain progression."

Data presented today showed that the median time to pain progression was 66.1 weeks for the satraplatin arm compared with 22.3 weeks for
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Electro Surgical Market" report to their ... expected to achieve a CAGR of 7% for ... benefits for patients as well as surgeons such ... visible marks, bleeding control and improved accuracy are ...
(Date:5/5/2015)... -- IQPC,s 19 th Software Design for Medical Devices ... Summit Mr. Phani Bidarahalli , GM & Head of ... expert speaker faculty including senior executive from GE Healthcare, Philips ... The Hotel Kabuki in San Francisco . ... the event website, which can be accessed by visiting ...
(Date:5/5/2015)... Lymphatic pump treatment (LPT) shows promise in managing pneumonia ... study published in The Journal of the American ... on infected rats three times a day followed by ... pneumonia. After 96 hours, over 60 percent of the ... of rats who received levofloxacin alone. Commonly ...
Breaking Medicine Technology:Global Electro Surgical Market 2015 2Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 2Lymphatic Pump Treatment Enhances Antibiotic Effectiveness for Treating Pneumonia 2
(Date:5/5/2015)... Jacksonville, Fla. (PRWEB) May 05, 2015 ... from the Commission on Cancer (CoC) of the American ... a cancer program must meet more than 30 Commission ... years through a survey process, and maintain levels of ... , When patients choose to seek care locally ...
(Date:5/5/2015)... Nutritional science and medical research has enabled ... health conditions and illnesses linked to carrying excess weight. ... eating methods to rid the body of dangerous toxins, ... fast and processed foods. Patients find the company’s ... report feeling better and losing excess fat within days. ...
(Date:5/5/2015)... 05, 2015 In a April 25, 2015, ... Herald-Times , the Missouri State Highway Patrol (MSHP) announced that ... or use for the second year in a row. ... FBI, reported 1,469 incidents in 2014 alone, around 15% of ... 2% of the US Population calls Indiana home, according to ...
(Date:5/5/2015)... Information Innovators Inc. (“Triple-i”), ... government, today announced its acquisition of Creative ... exclusively to federal government customers through its highly ... health services, and program management support. The company ... a Third Party Assessment Organization (3PAO) for cloud ...
(Date:5/5/2015)... Freeport, Grand Bahama (PRWEB) May 05, 2015 ... published its Orthopedic Lifestyle Report today. The study was ... orthopedic conditions such as osteoarthritis and sports-related ... chronic pain and stiffness was the most prevalent symptom ... reduced functionality such as walking, standing and bending over. ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3
... Giving shot 2 weeks earlier reduces the time babies ... 3 (HealthDay News) -- Giving infants a routine pertussis ... prevent at least 1,236 cases of pertussis, 898 hospitalizations ... a new study finds. , Researchers at Wake Forest ...
... the top 100, EL SEGUNDO, Calif., Nov. ... care services for those diagnosed with chronic kidney,failure ... 100 of Modern Healthcare,s,Best Places to Work in ... only nationwide healthcare services company on the list., ...
... Inc. and to Continue,Trading on NASDAQ under ... Cornerstone BioPharma,Holdings, Inc., a specialty pharmaceutical company ... respiratory disorders,today announced the completion of its ... biopharmaceutical company focused on,developing and commercializing innovative ...
... 3 Avineuro Pharmaceuticals, Inc.,announced today the completion ... for treatment of Alzheimer,s disease. These studies,demonstrate that ... it has a,favorable pharmacokinetic profile. Based on these ... AVN-101 into clinical,trials in Q1 2009. Results of ...
... adoption of daily home therapy continues to grow; ... LAWRENCE, Mass., Nov. 3 NxStage Medical, Inc.,(Nasdaq: ... dialysis products,today announced that 3,000 end-stage renal disease ... its NxStage(R) System One(TM), the,first truly portable home ...
... a leading provider of laser vision correction services under ... team will present at the Rodman & Renshaw 10th ... a.m. Eastern time. The,conference is being held at The ... A live and archived webcast of the event will ...
Cached Medicine News:Health News:Earlier Vaccination Could Cut Whooping Cough Deaths 2Health News:Modern Healthcare Names DaVita One of the Best Places to Work 2Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 2Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 3Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 4Health News:Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics 5Health News:NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy 2Health News:NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy 3Health News:NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy 4
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Refresh Contacts provides moisturizing relief from dryness and irritation associated with lens wear....
Specially formulated to lubricate and moisten lenses to help relieve irritation and dryness....
... Renu Multiplus preservative free ... and moisturize your eyes while ... The gentle preservative free formula ... may be sensitive to preservatives ...
Medicine Products: